Are you over 18 and want to see adult content?
More Annotations
A complete backup of michellebcooper.com
Are you over 18 and want to see adult content?
A complete backup of cosquillitasenlapanza2011.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of quickbooks-training.net
Are you over 18 and want to see adult content?
A complete backup of kurtzimmermann.com
Are you over 18 and want to see adult content?
A complete backup of muatkhong-25.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of aprilamente.info
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of scapinoballet.nl
Are you over 18 and want to see adult content?
A complete backup of planeindustries.com
Are you over 18 and want to see adult content?
A complete backup of brewsourcellc.com
Are you over 18 and want to see adult content?
A complete backup of sailtraininginternational.org
Are you over 18 and want to see adult content?
Text
DRUG DISCOVERY
DNDi is committed to exploring the potential contributions of open and collaborative science, in a bid to be accountable for our research working in the public interest.Science works through sharing and collaborating, and doing so can notably attract additional world-class researchers to a neglected field, enabling better results, faster and cheaper by reducing duplication. OPEN SYNTHESIS NETWORK How the Open Synthesis Network works . Drugs for Neglected Diseases initiative will share data on existing compounds, from one of its active research projects, with university participants, along with a list of new, “wanted” chemical compounds. Students can then explore the existing data, understand the design rationale for the new compounds through open discussion with DNDi experts, andANNUAL REPORTS
We have over 15 years of non-profit research. Download our Annual Reports, Financial and Performance Reports, and Research and Development Programmes in Review.CHARLES MOWBRAY
Dr Mowbray joined DNDi in August 2011 with responsibility for lead optimization in drug discovery projects.. Prior to joining DNDi, Dr Mowbray spent 19 years at Pfizer Worldwide Research and Development where he was most recently a Research Fellow in Worldwide Medicinal Chemistry at the Sandwich Laboratories, UK. During this time he developed experience as a medicinal chemist, project 2019 DNDI FINANCIAL AND PERFORMANCE REPORT International non-profit developing safe, effective, and affordable treatments for the most neglected patients.FRANÇOIS BOMPART
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trialLAURENCE VIELFAURE
Ms Vielfaure is DNDi‘s Finance Director.She joined DNDi as its Financial Controller in 2005. In her role, she develops and implements financial controls and budgets, and also coordinates financial reporting with the fundraising department. STUDY FOR A CHILD-FRIENDLY HIV TREATMENT BEGINS IN UGANDA The phase I/II study, called LOLIPOP, will provide clinical data on the 4-in-1 in infants and young children.The first children were enrolled at the Mbarara Regional Referral Hospital by Epicentre, which conducts field research in support of Doctors Without Borders/Médecins Sans Frontières (MSF). ANTIMICROBIAL RESISTANCE PROJECT PROPOSALS 5 | P a g e Theuretzbacher U, Paul M: Revival of old antibiotics: structuring the re-development process to optimize usage.Clin Microbiol Infect. 2015 Oct;21(10):878-80. Theuretzbacher U, Van Bambeke F, Cantón R, Giske CG, Mouton JW, Nation RL, Paul M, TurnidgeJD,
DNDI | BEST SCIENCE FOR THE MOST NEGLECTEDCOVID-19NEWS & RESOURCESABOUT USDONATEDISEASESRESEARCH & DEVELOPMENT DNDi has created medical history for neglected patients. Since 2003, we have developed 8 affordable treatments for 5 deadly diseases, saving millions of lives.DRUG DISCOVERY
DNDi is committed to exploring the potential contributions of open and collaborative science, in a bid to be accountable for our research working in the public interest.Science works through sharing and collaborating, and doing so can notably attract additional world-class researchers to a neglected field, enabling better results, faster and cheaper by reducing duplication. OPEN SYNTHESIS NETWORK How the Open Synthesis Network works . Drugs for Neglected Diseases initiative will share data on existing compounds, from one of its active research projects, with university participants, along with a list of new, “wanted” chemical compounds. Students can then explore the existing data, understand the design rationale for the new compounds through open discussion with DNDi experts, andANNUAL REPORTS
We have over 15 years of non-profit research. Download our Annual Reports, Financial and Performance Reports, and Research and Development Programmes in Review.CHARLES MOWBRAY
Dr Mowbray joined DNDi in August 2011 with responsibility for lead optimization in drug discovery projects.. Prior to joining DNDi, Dr Mowbray spent 19 years at Pfizer Worldwide Research and Development where he was most recently a Research Fellow in Worldwide Medicinal Chemistry at the Sandwich Laboratories, UK. During this time he developed experience as a medicinal chemist, project 2019 DNDI FINANCIAL AND PERFORMANCE REPORT International non-profit developing safe, effective, and affordable treatments for the most neglected patients.FRANÇOIS BOMPART
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trialLAURENCE VIELFAURE
Ms Vielfaure is DNDi‘s Finance Director.She joined DNDi as its Financial Controller in 2005. In her role, she develops and implements financial controls and budgets, and also coordinates financial reporting with the fundraising department. STUDY FOR A CHILD-FRIENDLY HIV TREATMENT BEGINS IN UGANDA The phase I/II study, called LOLIPOP, will provide clinical data on the 4-in-1 in infants and young children.The first children were enrolled at the Mbarara Regional Referral Hospital by Epicentre, which conducts field research in support of Doctors Without Borders/Médecins Sans Frontières (MSF). ANTIMICROBIAL RESISTANCE PROJECT PROPOSALS 5 | P a g e Theuretzbacher U, Paul M: Revival of old antibiotics: structuring the re-development process to optimize usage.Clin Microbiol Infect. 2015 Oct;21(10):878-80. Theuretzbacher U, Van Bambeke F, Cantón R, Giske CG, Mouton JW, Nation RL, Paul M, TurnidgeJD,
DNDI GLOBAL HEADQUARTERS Established in 2003 in Geneva, Switzerland, DNDi’s global headquarters office is active in Research & Development activities, as well as in administrative and support departments, including finance, human resources, IT, policy advocacy, communications, and fundraising.The team manages projects and partnerships so that new and adapted treatments are developed for sleeping sickness TARGET PRODUCT PROFILE FOR COVID-19 Target product profile for mild/moderate outpatient COVID-19. The ANTICOV consortium, led by DNDi, aims to identify treatments suitable for outpatient delivery to prevent the progression of mild or moderate COVID-19 to severe disease and spikes in hospitalizations that could overwhelm overburdened health systems in low-resource settings. BEYOND THE JAB: A NEED FOR GLOBAL COORDINATION OF by Naniche D, Hotez P, Bottazzi ME, Ergonul O, Figueroa JP, Gilbert S, Gursel M, Hassanain M, Kang G, Kaslow D, Kim JH, Lall B, Larson H, Sheahan T, Shoham S,CONTACT US | DNDI
15 Chemin Camille-Vidart 1202 Geneva Switzerland Tel: +41 22 906 9230 Fax: +41 22 906 9231 Email: dndi@dndi.orgANNUAL REPORTS
We have over 15 years of non-profit research. Download our Annual Reports, Financial and Performance Reports, and Research and Development Programmes in Review.OUR LEADERSHIP
DNDi’s diverse global team of around 250 staff and close consultants represent more than 30 nationalities and bring essential skills and experience from the the academic, non-profit, private, and public sectors.. Our colleagues leading activities across DNDi programmes, departments, and regional offices are listed below. ADMINISTRATIVE AND POLICY INTERN Interested in being part of an international non-profit organization? Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for a range of neglected diseases (www.dndi.org).DNDi’s primary objective is to deliver 25 new treatments in our first 25 years toTHE STORM-C-1 TRIAL
which is more prevalent in high-income countries, and genotype . 3 (25% of infections), which is more prevalent in low- and . middle-income countries and is harder to treat with DAAs. SENIOR REGULATORY AFFAIRS MANAGER The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected DELIVER 18 NEW TREATMENTS BY 2028 The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected DNDI | BEST SCIENCE FOR THE MOST NEGLECTEDCOVID-19NEWS & RESOURCESABOUT USDONATEDISEASESRESEARCH & DEVELOPMENT DNDi has created medical history for neglected patients. Since 2003, we have developed 8 affordable treatments for 5 deadly diseases, saving millions of lives. DNDI GLOBAL HEADQUARTERS Established in 2003 in Geneva, Switzerland, DNDi’s global headquarters office is active in Research & Development activities, as well as in administrative and support departments, including finance, human resources, IT, policy advocacy, communications, and fundraising.The team manages projects and partnerships so that new and adapted treatments are developed for sleeping sicknessDRUG DISCOVERY
Drug Discovery. It all starts in the compound library. DND i invests in bringing all-new treatments through the research and development (R&D) pipeline – both by repurposing or modifying drugs from other therapeutic areas and by identifying and developing entirely new chemical entities. We work with partners around the world: OPEN SYNTHESIS NETWORK Registration & access. Launched in 2015, the Open Synthesis Network (OSN) is a collaborative project that aims to engage master’s and undergraduate students in research for neglected diseases. Currently the OSN has 20 participating institutions around the world. Students are working on compounds that kill leishmania donovani and leishmaniaANNUAL REPORTS
We have over 15 years of non-profit research. Download our Annual Reports, Financial and Performance Reports, and Research and Development Programmes in Review.CHARLES MOWBRAY
Dr Mowbray joined DNDi in August 2011 with responsibility for lead optimization in drug discovery projects.. Prior to joining DNDi, Dr Mowbray spent 19 years at Pfizer Worldwide Research and Development where he was most recently a Research Fellow in Worldwide Medicinal Chemistry at the Sandwich Laboratories, UK. During this time he developed experience as a medicinal chemist, projectFRANÇOIS BOMPART
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial ANTIMICROBIAL RESISTANCE PROJECT PROPOSALS 5 | P a g e Theuretzbacher U, Paul M: Revival of old antibiotics: structuring the re-development process to optimize usage.Clin Microbiol Infect. 2015 Oct;21(10):878-80. Theuretzbacher U, Van Bambeke F, Cantón R, Giske CG, Mouton JW, Nation RL, Paul M, TurnidgeJD,
LAURENCE VIELFAURE
Director of Finance, DND i. Ms Vielfaure is DND i ‘s Finance Director. She joined DND i as its Financial Controller in 2005. In her role, she develops and implements financial controls and budgets, and also coordinates financial reporting with the fundraising department. Most recently, she was a teacher at the Bioforce Development School STUDY FOR A CHILD-FRIENDLY HIV TREATMENT BEGINS IN UGANDA Study for a child-friendly HIV treatment begins in Uganda. The first patients have been enrolled in a potentially ground-breaking trial in Uganda for a capsule of granules containing four HIV drugs that can be easily administered to young children. Known as the ‘4-in-1,’ this sweet-tasting ‘fixed-dose combination’ could constitute a DNDI | BEST SCIENCE FOR THE MOST NEGLECTEDCOVID-19NEWS & RESOURCESABOUT USDONATEDISEASESRESEARCH & DEVELOPMENT DNDi has created medical history for neglected patients. Since 2003, we have developed 8 affordable treatments for 5 deadly diseases, saving millions of lives. DNDI GLOBAL HEADQUARTERS Established in 2003 in Geneva, Switzerland, DNDi’s global headquarters office is active in Research & Development activities, as well as in administrative and support departments, including finance, human resources, IT, policy advocacy, communications, and fundraising.The team manages projects and partnerships so that new and adapted treatments are developed for sleeping sicknessDRUG DISCOVERY
Drug Discovery. It all starts in the compound library. DND i invests in bringing all-new treatments through the research and development (R&D) pipeline – both by repurposing or modifying drugs from other therapeutic areas and by identifying and developing entirely new chemical entities. We work with partners around the world: OPEN SYNTHESIS NETWORK Registration & access. Launched in 2015, the Open Synthesis Network (OSN) is a collaborative project that aims to engage master’s and undergraduate students in research for neglected diseases. Currently the OSN has 20 participating institutions around the world. Students are working on compounds that kill leishmania donovani and leishmaniaANNUAL REPORTS
We have over 15 years of non-profit research. Download our Annual Reports, Financial and Performance Reports, and Research and Development Programmes in Review.CHARLES MOWBRAY
Dr Mowbray joined DNDi in August 2011 with responsibility for lead optimization in drug discovery projects.. Prior to joining DNDi, Dr Mowbray spent 19 years at Pfizer Worldwide Research and Development where he was most recently a Research Fellow in Worldwide Medicinal Chemistry at the Sandwich Laboratories, UK. During this time he developed experience as a medicinal chemist, projectFRANÇOIS BOMPART
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial ANTIMICROBIAL RESISTANCE PROJECT PROPOSALS 5 | P a g e Theuretzbacher U, Paul M: Revival of old antibiotics: structuring the re-development process to optimize usage.Clin Microbiol Infect. 2015 Oct;21(10):878-80. Theuretzbacher U, Van Bambeke F, Cantón R, Giske CG, Mouton JW, Nation RL, Paul M, TurnidgeJD,
LAURENCE VIELFAURE
Director of Finance, DND i. Ms Vielfaure is DND i ‘s Finance Director. She joined DND i as its Financial Controller in 2005. In her role, she develops and implements financial controls and budgets, and also coordinates financial reporting with the fundraising department. Most recently, she was a teacher at the Bioforce Development School STUDY FOR A CHILD-FRIENDLY HIV TREATMENT BEGINS IN UGANDA Study for a child-friendly HIV treatment begins in Uganda. The first patients have been enrolled in a potentially ground-breaking trial in Uganda for a capsule of granules containing four HIV drugs that can be easily administered to young children. Known as the ‘4-in-1,’ this sweet-tasting ‘fixed-dose combination’ could constitute a DNDI GLOBAL HEADQUARTERS Established in 2003 in Geneva, Switzerland, DNDi’s global headquarters office is active in Research & Development activities, as well as in administrative and support departments, including finance, human resources, IT, policy advocacy, communications, and fundraising.The team manages projects and partnerships so that new and adapted treatments are developed for sleeping sicknessCONTACT US | DNDI
15 Chemin Camille-Vidart 1202 Geneva Switzerland Tel: +41 22 906 9230 Fax: +41 22 906 9231 Email: dndi@dndi.orgOUR LEADERSHIP
DNDi’s diverse global team of around 250 staff and close consultants represent more than 30 nationalities and bring essential skills and experience from the the academic, non-profit, private, and public sectors.. Our colleagues leading activities across DNDi programmes, departments, and regional offices are listed below.NEWS & RESOURCES
News & resources Loading All News Press releases Publications Scientific articles Statements Stories Videos Viewpoints 16 Apr 2021 15 Apr 2021 15 Apr 2021 TARGET PRODUCT PROFILE FOR COVID-19 Target product profile. for mild/moderate outpatient COVID-19. The ANTICOV consortium, led by DND i, aims to identify treatments suitable for outpatient delivery to prevent the progression of mild or moderate COVID-19 to severe disease and spikes in hospitalizations that could overwhelm overburdened health systems in low-resource settings. Ideal.ANNUAL REPORTS
We have over 15 years of non-profit research. Download our Annual Reports, Financial and Performance Reports, and Research and Development Programmes in Review. SENIOR REGULATORY AFFAIRS MANAGER The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected SENIOR LEGAL COUNSEL The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected INNOVATIVE SINGLE-DOSE ORAL SLEEPING SICKNESS TREATMENT TO Once approved, the treatment could be administered in a single dose at the point of diagnosis making it a game-changer to support the sustainable elimination of the disease.LAURENT FRAISSE
Laurent Fraisse joined the Drugs for Neglected Diseases initative (DNDi) as Research & Development (R&D) Director and Executive Team member in October 2019.In this capacity he drives DNDi’s science strategy and oversees all research and clinical activities worldwide.. Laurent is an experienced biotechnology and pharmaceutical executive, and a leading expert in infectious diseases, having led DNDI | BEST SCIENCE FOR THE MOST NEGLECTEDCOVID-19NEWS & RESOURCESABOUT USDONATEDISEASESRESEARCH & DEVELOPMENT DNDi has created medical history for neglected patients. Since 2003, we have developed 8 affordable treatments for 5 deadly diseases, saving millions of lives. DNDI GLOBAL HEADQUARTERS Established in 2003 in Geneva, Switzerland, DNDi’s global headquarters office is active in Research & Development activities, as well as in administrative and support departments, including finance, human resources, IT, policy advocacy, communications, and fundraising.The team manages projects and partnerships so that new and adapted treatments are developed for sleeping sicknessDRUG DISCOVERY
Drug Discovery. It all starts in the compound library. DND i invests in bringing all-new treatments through the research and development (R&D) pipeline – both by repurposing or modifying drugs from other therapeutic areas and by identifying and developing entirely new chemical entities. We work with partners around the world: WHO 2030 NTDS ROADMAP: HOW SCIENCE AND PARTNERSHIPS CAN On 28 January 2021 the World Health Organization (WHO) launched its new 2030 Roadmap, which sets the direction in the response against neglected tropical diseases (NTDs) for the next decade.. Dr Nathalie Strub-Wourgaft, DNDi’s director of NTDs, explains what must be done to make the Roadmap a success.. What progress has been made since the launch of the previous WHO NTD Roadmap in 2011? OPEN SYNTHESIS NETWORK Registration & access. Launched in 2015, the Open Synthesis Network (OSN) is a collaborative project that aims to engage master’s and undergraduate students in research for neglected diseases. Currently the OSN has 20 participating institutions around the world. Students are working on compounds that kill leishmania donovani and leishmaniaANNUAL REPORTS
We have over 15 years of non-profit research. Download our Annual Reports, Financial and Performance Reports, and Research and Development Programmes in Review.CHARLES MOWBRAY
Dr Mowbray joined DNDi in August 2011 with responsibility for lead optimization in drug discovery projects.. Prior to joining DNDi, Dr Mowbray spent 19 years at Pfizer Worldwide Research and Development where he was most recently a Research Fellow in Worldwide Medicinal Chemistry at the Sandwich Laboratories, UK. During this time he developed experience as a medicinal chemist, projectFRANÇOIS BOMPART
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trialLAURENCE VIELFAURE
Director of Finance, DND i. Ms Vielfaure is DND i ‘s Finance Director. She joined DND i as its Financial Controller in 2005. In her role, she develops and implements financial controls and budgets, and also coordinates financial reporting with the fundraising department. Most recently, she was a teacher at the Bioforce Development School STUDY FOR A CHILD-FRIENDLY HIV TREATMENT BEGINS IN UGANDA Study for a child-friendly HIV treatment begins in Uganda. The first patients have been enrolled in a potentially ground-breaking trial in Uganda for a capsule of granules containing four HIV drugs that can be easily administered to young children. Known as the ‘4-in-1,’ this sweet-tasting ‘fixed-dose combination’ could constitute a DNDI | BEST SCIENCE FOR THE MOST NEGLECTEDCOVID-19NEWS & RESOURCESABOUT USDONATEDISEASESRESEARCH & DEVELOPMENT DNDi has created medical history for neglected patients. Since 2003, we have developed 8 affordable treatments for 5 deadly diseases, saving millions of lives. DNDI GLOBAL HEADQUARTERS Established in 2003 in Geneva, Switzerland, DNDi’s global headquarters office is active in Research & Development activities, as well as in administrative and support departments, including finance, human resources, IT, policy advocacy, communications, and fundraising.The team manages projects and partnerships so that new and adapted treatments are developed for sleeping sicknessDRUG DISCOVERY
Drug Discovery. It all starts in the compound library. DND i invests in bringing all-new treatments through the research and development (R&D) pipeline – both by repurposing or modifying drugs from other therapeutic areas and by identifying and developing entirely new chemical entities. We work with partners around the world: WHO 2030 NTDS ROADMAP: HOW SCIENCE AND PARTNERSHIPS CAN On 28 January 2021 the World Health Organization (WHO) launched its new 2030 Roadmap, which sets the direction in the response against neglected tropical diseases (NTDs) for the next decade.. Dr Nathalie Strub-Wourgaft, DNDi’s director of NTDs, explains what must be done to make the Roadmap a success.. What progress has been made since the launch of the previous WHO NTD Roadmap in 2011? OPEN SYNTHESIS NETWORK Registration & access. Launched in 2015, the Open Synthesis Network (OSN) is a collaborative project that aims to engage master’s and undergraduate students in research for neglected diseases. Currently the OSN has 20 participating institutions around the world. Students are working on compounds that kill leishmania donovani and leishmaniaANNUAL REPORTS
We have over 15 years of non-profit research. Download our Annual Reports, Financial and Performance Reports, and Research and Development Programmes in Review.CHARLES MOWBRAY
Dr Mowbray joined DNDi in August 2011 with responsibility for lead optimization in drug discovery projects.. Prior to joining DNDi, Dr Mowbray spent 19 years at Pfizer Worldwide Research and Development where he was most recently a Research Fellow in Worldwide Medicinal Chemistry at the Sandwich Laboratories, UK. During this time he developed experience as a medicinal chemist, projectFRANÇOIS BOMPART
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trialLAURENCE VIELFAURE
Director of Finance, DND i. Ms Vielfaure is DND i ‘s Finance Director. She joined DND i as its Financial Controller in 2005. In her role, she develops and implements financial controls and budgets, and also coordinates financial reporting with the fundraising department. Most recently, she was a teacher at the Bioforce Development School STUDY FOR A CHILD-FRIENDLY HIV TREATMENT BEGINS IN UGANDA Study for a child-friendly HIV treatment begins in Uganda. The first patients have been enrolled in a potentially ground-breaking trial in Uganda for a capsule of granules containing four HIV drugs that can be easily administered to young children. Known as the ‘4-in-1,’ this sweet-tasting ‘fixed-dose combination’ could constitute a DNDI GLOBAL HEADQUARTERS Established in 2003 in Geneva, Switzerland, DNDi’s global headquarters office is active in Research & Development activities, as well as in administrative and support departments, including finance, human resources, IT, policy advocacy, communications, and fundraising.The team manages projects and partnerships so that new and adapted treatments are developed for sleeping sicknessCONTACT US | DNDI
15 Chemin Camille-Vidart 1202 Geneva Switzerland Tel: +41 22 906 9230 Fax: +41 22 906 9231 Email: dndi@dndi.org TARGET PRODUCT PROFILE FOR COVID-19 Target product profile. for mild/moderate outpatient COVID-19. The ANTICOV consortium, led by DND i, aims to identify treatments suitable for outpatient delivery to prevent the progression of mild or moderate COVID-19 to severe disease and spikes in hospitalizations that could overwhelm overburdened health systems in low-resource settings. Ideal.OUR LEADERSHIP
DNDi’s diverse global team of around 250 staff and close consultants represent more than 30 nationalities and bring essential skills and experience from the the academic, non-profit, private, and public sectors.. Our colleagues leading activities across DNDi programmes, departments, and regional offices are listed below.NEWS & RESOURCES
News & resources Loading All News Press releases Publications Scientific articles Statements Stories Videos Viewpoints 16 Apr 2021 15 Apr 2021 15 Apr 2021 SENIOR LEGAL COUNSEL The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected DELIVER 18 NEW TREATMENTS BY 2028 The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected INNOVATIVE SINGLE-DOSE ORAL SLEEPING SICKNESS TREATMENT TO Once approved, the treatment could be administered in a single dose at the point of diagnosis making it a game-changer to support the sustainable elimination of the disease.LAURENT FRAISSE
Laurent Fraisse joined the Drugs for Neglected Diseases initative (DNDi) as Research & Development (R&D) Director and Executive Team member in October 2019.In this capacity he drives DNDi’s science strategy and oversees all research and clinical activities worldwide.. Laurent is an experienced biotechnology and pharmaceutical executive, and a leading expert in infectious diseases, having ledBEN PERRY | DNDI
Ben Perry, Discovery Open Innovation Leader, joined DNDi in April 2015 as Project Manager of the NTD Drug Discovery Booster project.. Ben is a medicinal chemist with over 15 years’ experience conducting early stage drug discovery across a variety of disease indications including oncology, autoimmune disorders, and psychiatry. DNDI | BEST SCIENCE FOR THE MOST NEGLECTEDCOVID-19NEWS & RESOURCESABOUT USDONATEDISEASESRESEARCH & DEVELOPMENT DNDi has created medical history for neglected patients. Since 2003, we have developed 8 affordable treatments for 5 deadly diseases, saving millions of lives.DRUG DISCOVERY
DNDi is committed to exploring the potential contributions of open and collaborative science, in a bid to be accountable for our research working in the public interest.Science works through sharing and collaborating, and doing so can notably attract additional world-class researchers to a neglected field, enabling better results, faster and cheaper by reducing duplication.ANNUAL REPORTS
We have over 15 years of non-profit research. Download our Annual Reports, Financial and Performance Reports, and Research and Development Programmes in Review. OPEN SYNTHESIS NETWORK How the Open Synthesis Network works . Drugs for Neglected Diseases initiative will share data on existing compounds, from one of its active research projects, with university participants, along with a list of new, “wanted” chemical compounds. Students can then explore the existing data, understand the design rationale for the new compounds through open discussion with DNDi experts, and 2019 DNDI FINANCIAL AND PERFORMANCE REPORT International non-profit developing safe, effective, and affordable treatments for the most neglected patients.FRANÇOIS BOMPART
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trialCHARLES MOWBRAY
Dr Mowbray joined DNDi in August 2011 with responsibility for lead optimization in drug discovery projects.. Prior to joining DNDi, Dr Mowbray spent 19 years at Pfizer Worldwide Research and Development where he was most recently a Research Fellow in Worldwide Medicinal Chemistry at the Sandwich Laboratories, UK. During this time he developed experience as a medicinal chemist, projectLAURENCE VIELFAURE
Ms Vielfaure is DNDi‘s Finance Director.She joined DNDi as its Financial Controller in 2005. In her role, she develops and implements financial controls and budgets, and also coordinates financial reporting with the fundraising department. UNITING TO COMBAT NEGLECTED LONDON DECLARATION ON … london declaration on neglected tropical diseases embargo: 30 january 2012 – 11:00 a.m. gmt uniting to combat neglected tropical diseases ending the neglect & reaching 2020 goalsNEWS - DNDI
2. News. Drug Approval . The PPB has provisions for fast-track applications based on specific policy . guidelines, which state that fast-track submissions have a product approval DNDI | BEST SCIENCE FOR THE MOST NEGLECTEDCOVID-19NEWS & RESOURCESABOUT USDONATEDISEASESRESEARCH & DEVELOPMENT DNDi has created medical history for neglected patients. Since 2003, we have developed 8 affordable treatments for 5 deadly diseases, saving millions of lives.DRUG DISCOVERY
DNDi is committed to exploring the potential contributions of open and collaborative science, in a bid to be accountable for our research working in the public interest.Science works through sharing and collaborating, and doing so can notably attract additional world-class researchers to a neglected field, enabling better results, faster and cheaper by reducing duplication.ANNUAL REPORTS
We have over 15 years of non-profit research. Download our Annual Reports, Financial and Performance Reports, and Research and Development Programmes in Review. OPEN SYNTHESIS NETWORK How the Open Synthesis Network works . Drugs for Neglected Diseases initiative will share data on existing compounds, from one of its active research projects, with university participants, along with a list of new, “wanted” chemical compounds. Students can then explore the existing data, understand the design rationale for the new compounds through open discussion with DNDi experts, and 2019 DNDI FINANCIAL AND PERFORMANCE REPORT International non-profit developing safe, effective, and affordable treatments for the most neglected patients.FRANÇOIS BOMPART
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trialCHARLES MOWBRAY
Dr Mowbray joined DNDi in August 2011 with responsibility for lead optimization in drug discovery projects.. Prior to joining DNDi, Dr Mowbray spent 19 years at Pfizer Worldwide Research and Development where he was most recently a Research Fellow in Worldwide Medicinal Chemistry at the Sandwich Laboratories, UK. During this time he developed experience as a medicinal chemist, projectLAURENCE VIELFAURE
Ms Vielfaure is DNDi‘s Finance Director.She joined DNDi as its Financial Controller in 2005. In her role, she develops and implements financial controls and budgets, and also coordinates financial reporting with the fundraising department. UNITING TO COMBAT NEGLECTED LONDON DECLARATION ON … london declaration on neglected tropical diseases embargo: 30 january 2012 – 11:00 a.m. gmt uniting to combat neglected tropical diseases ending the neglect & reaching 2020 goalsNEWS - DNDI
2. News. Drug Approval . The PPB has provisions for fast-track applications based on specific policy . guidelines, which state that fast-track submissions have a product approvalCONTACT US | DNDI
15 Chemin Camille-Vidart 1202 Geneva Switzerland Tel: +41 22 906 9230 Fax: +41 22 906 9231 Email: dndi@dndi.orgCLINICAL TRIALS
At DNDi, we work with research partners from around the world to evaluate new and improved medicines and treatment regimens in clinical trials.The evidence from these studies enables us to deliver better, more affordable treatments for the most neglected. We conduct world-class clinical trials following Good Clinical Practice standards even in the most remote and rural areas.NEWS & RESOURCES
News & resources Loading All News Press releases Publications Scientific articles Statements Stories Videos Viewpoints 16 Apr 2021 15 Apr 2021 15 Apr 2021 INNOVATIVE SINGLE-DOSE ORAL SLEEPING SICKNESS TREATMENT TO Once approved, the treatment could be administered in a single dose at the point of diagnosis making it a game-changer to support the sustainable elimination of the disease.KAORI NAKATANI
Kaori Nakatani joined DNDi in January 2020 as Head of Japan Liaison Office.. Kaori started her career in a non-profit organization, managing development programmes in East Africa. Since then and for the last 20 years, Kaori worked for UNAIDS, UNDP, and JICA, focusing on public health and universal coverage.LAURENT FRAISSE
Laurent Fraisse joined the Drugs for Neglected Diseases initative (DNDi) as Research & Development (R&D) Director and Executive Team member in October 2019.In this capacity he drives DNDi’s science strategy and oversees all research and clinical activities worldwide.. Laurent is an experienced biotechnology and pharmaceutical executive, and a leading expert in infectious diseases, having ledCAROL RUFFELL
Carol Ruffell is an experienced specialist in the global public health sector, having worked primarily within the HIV/AIDS and TB arena. She is an experienced executive with knowledge of the global public health system and good insight of the Southern African health sector.WENDY KELLER
Wendy Keller joined DNDi in December 2014 as Quality Assurance Manager.. Wendy has 17 years of experience in Good Clinical Practice Quality Assurance and Compliance during which she has been involved in international auditing, GCP training, Trial Team support andSUERIE MOON
Suerie Moon is Co-Director at the Global Health Centre, Graduate Institute of International and Development Studies, Geneva, which shejoined in 2016.
DNDI INDIA | DNDI
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.Skip to content
_ _ INTERNATIONAL
* DND_i_ JAPAN
* DND_i_ LATIN AMERICA * DND_i_ NORTH AMERICA* YouTube
* RSS
__Menu
* ABOUT US__
*
*
* ABOUT US
* BUSINESS MODEL
* DND_i_‘s POLICIES* DND_i_ WORLDWIDE
* OUR PEOPLE
*
*
* ANNUAL REPORTS
* JOB OPPORTUNITIES
* REQUESTS FOR PROPOSALS* CONTACT US
* __ Close
* DISEASES & PROJECTS__*
*
* DISEASES
* SLEEPING SICKNESS
* LEISHMANIASIS
* CHAGAS DISEASE
* PAEDIATRIC HIV
*
*
* FILARIAL DISEASE
* MYCETOMA
* HEPATITIS C
*
*
* PROJECT PORTFOLIO
*
*
*
* TARGET PRODUCT PROFILES* CLINICAL TRIALS
* OPEN INNOVATION PORTAL* __ Close
* ACHIEVEMENTS__
*
* DND_i_ ACHIEVEMENTS* FEXINIDAZOLE
_Sleeping sickness_
* GLOBAL ANTIBIOTIC R&D PARTNERSHIP (GARDP) * SUPER-BOOSTER THERAPY_Paediatric HIV/TB_
* NEW VL TREATMENTS SOUTH ASIA _Visceral leishmaniasis_*
* PAEDIATRIC BENZNIDAZOLE_Chagas_
* SSG&PM
_Visceral leishmaniasis_* NECT
_Sleeping sickness_
* ASMQ
_Malaria_
* ASAQ
_Malaria_
* __ Close
* STRENGTHENING CAPACITY__*
*
* OVERVIEW
* TECHNOLOGY TRANSFERS*
*
* CHAGAS PLATFORM
* HAT PLATFORM
* LEAP PLATFORM
* REDELEISH NETWORK
* __ Close
* ADVOCACY__
*
* ADVOCACY UPDATES
* ACCESS
* INTELLECTUAL PROPERTY* __ Close
* NEWS & RESOURCES__*
*
* OVERVIEW
* NEWS, VIEWS & STORIES* PRESS RELEASES
* IN THE MEDIA
*
*
* OUR PUBLICATIONS
* ENEWS NEWSLETTER
* VIDEOS
* SCIENTIFIC ARTICLES* EVENTS
* __ Close
* PARTNERS__
*
* OVERVIEW
* BUSINESS MODEL
* PARTNERS
* BECOME A DND_i_ PARTNER* __ Close
* DONATE__
*
* DONATE
* HOW TO HELP
* DONORS
* TRANSPARENCY
* KEY FINANCIAL FIGURES* __ Close
* ____
*
Search __ Search
* __ Close
NOVARTIS AND DND_I_ TO COLLABORATE ON THE DEVELOPMENT OF A NEW ORAL DRUG TO TREAT VISCERAL LEISHMANIASIS We have signed an innovative collaboration and licence agreement with Novartis to jointly develop LXE408, a potential new oral treatment for visceral leishmaniasis. Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis 2019 R&D PORTFOLIO IN REVIEW Read updates on our R&D projects for sleeping sickness, leishmaniasis, Chagas disease, filarial diseases, mycetoma, paediatric HIV, and hepatitis C. 2019 R&D Portfolio in Review HIV TREATMENT FOR CHILDREN TO BE PRODUCED FOR UNDER ONE DOLLAR A DAY Cipla has announced their commitment to price the ground-breaking new product Quadrimune, a “4-in-1” treatment for young children with HIV, at $1 a day or less. Quadrimune was developed in partnership with DND_i_ and is currently under review by the US FDA. HIV treatment for children to be produced for under one dollar a day DND_I_ RECEIVES $29 MILLION TO FAST-TRACK THE DEVELOPMENT OF DRUGS TO HELP ELIMINATE SLEEPING SICKNESS AND RIVER BLINDNESS The grants will run from 2020 until 2023 and will help deliver a single-dose cure for sleeping sickness and greatly aid efforts to develop a short-course treatment for the millions of people at risk of river blindness in Central and West Africa. DNDi receives $29 million to fast-track the development of drugs to help eliminate sleeping sickness and river blindness PUBLIC-PRIVATE PARTNERSHIP LAUNCHED TO DEVELOP NEW DRUGS FOR ROUNDWORMINFECTIONS
The Helminth Elimination Platform (HELP) brings together research institutes, universities, not-for-profit organizations, and pharmaceutical companies to develop novel drugs for infections caused by parasitic worms (helminths). Public-private partnership launched to develop new drugs for roundworm infections* __
* __
* __
* __
* __
NEGLECTED PATIENTS
Neglected diseases continue to cause significant morbidity and mortality in the developing world. Yet, of the 850 new therapeutic products approved between 2000 and 2011, only 4% (and only 1% of all approved NCEs) were indicated for neglected diseases, even though these diseases account for 11% of the global disease burden.SLEEPING SICKNESS
Sleeping sickness is endemic in 36 African countries. 8.5 million people are at medium to high risk of being infected.LEISHMANIASIS
1 billion people are at risk of leishmaniasis worldwide. Visceral leishmaniasis kills an estimated 20,000-30,000 people annually.CHAGAS DISEASE
Chagas disease is endemic in 21 Latin American countries where it kills more people than malaria. Less than 1% of patients have accessto treatment.
PAEDIATRIC HIV
1.7 million children below 15 years of age are living with HIV globally, mainly in sub-Saharan Africa, and 300 of them die every day.FILARIAL DISEASE
Over 21 million people are infected with onchocerciasis (river blindness), and 205 million people are at risk.MYCETOMA
Stigmatizing disease often resulting in devastating deformities, amputation, and morbidity. Treatment success for eumycetoma is lessthan 35%.
HEPATITIS C
71 million people worldwide chronically infected in 2015, of which 75% live in low- and middle-income countries. NEWS & PRESS RELEASES * 2019 R&D portfolio in review: Sleeping sickness * 2019 R&D portfolio in review: Leishmaniasis * 2019 R&D portfolio in review: Chagas disease * 2019 R&D portfolio in review: Filaria – river blindness * 2019 R&D portfolio in review: MycetomaSCIENTIFIC ARTICLES
* Patients’ preferences of cutaneous leishmaniasis treatment outcomes: Findings from an international qualitative study * Abacavir exposure in children co-treated for tuberculosis with rifampicin and super-boosted lopinavir-ritonavir * Prioritising pathogens for the management of severe febrile patients to improve clinical care in low- and middle-income countriesIN THE MEDIA
* The Week: “Clinical trials on for an advanced oral drug forkala-azar”
* Science Africa: “Novartis and DND_i_ targets to treat visceralleishmaniasis”
* The Hindu Business Line: “Global clinical trial for drug to treat Kala Azar to take place in 2021” * The Guardian: “‘The job is not done’: the fight to combat neglected tropical diseases” * Forbes: “Global health technologes: Time to re-think the ‘Trickle Down’ model”EVENTS
* CROI 2020
8-11 March
2020 BOSTON, UNITED STATES * Isabelle Andrieux-Meyer, Head of Clinical Development HIV & Hepatitis C Initiative - symposium on hepatitis C * Next Einstein Forum Global Gathering 2020 10-13 March 2020 NAIROBI, KENYA * Monique Wasunna, Director Africa Regional Office - session on building clinical trials capacity in Africa * IS Global XVI Workshop on Chagas disease 12 March 2020 BARCELONA, SPAIN * Fabiana Barreira, Chagas Senior Clinical Project and Medical Manager - presentation of the fexi-12 study results * Andrea Marchiol, Chagas Access Project Manager - presentation of cost-benefit analysis of a Chagas disease project in Colombia* AFRAVIH 2020
15-19
April 2020 LONDON, UK * François Bompart, Director HIV and Hepatitis C Initiative - symposia on paediatric HIV__ A GLOBAL TEAM
230 STAFF IN: Geneva/ Cape Town
/
Kinshasa
/ Kuala Lumpur
/ Nairobi
/ New
Delhi
/ New
York City
/ Rio
de Janeiro
/
Tokyo
DND_i_ works through over 160 partnerships and 4 clinical trial platforms and networks thanks to the generous support of our donors .7 founding partners
joined forces to
establish DND_i_: 5 public sector institutions, one humanitarian organization, one international research organization.__ R&D PORTFOLIO
*
DISCOVERY
*
TRANSLATION
*
DEVELOPMENT
*
IMPLEMENTATION
DISCOVERY PROJECTS
* SCYX1330682 & SCYX-1608210* Screening
* Leishmaniasis Hit-to-lead * NTD Drug Discovery Booster Hit-to-lead * Daiichi Sankyo Hit-to-lead * DNDI-5421 & DNDI-5610* Aminopyrazoles
* CF series
* Leishmaniasis L205 Series* Screening
* Chagas Hit-to-lead * NTD Drug Discovery Booster Hit-to-lead * Daiichi Sankyo Hit-to-lead * Chagas C205 Series TRANSLATION PROJECTS* DNDI-6174
* GSK3494245 DDD1305143* CpG-D35 for CL
* DNDI-6148
* DNDI-0690
* GSK3186899 DDD853651* Biomarkers
* Fexinidazole for Chagas * Macrofilaricide CC6166* Oxfendazole
* Emodepside
* TylAMac (ABBV-4083) * 5 FC (cryptococcal meningitis) DEVELOPMENT PROJECTS* Acoziborole
* Fexinidazole for _T.b. rhodesiense_ * New CL combination * New treatments for PKDL * Miltefosine + paramomycin combination (Africa) * New VL treatments (Latin America) * New treatments for HIV/VL * New benznidazole regimens* Fosravuconazole
* 4-in-1 (ABC/3TC/LPV/r) * Ravidasvir + sofosbuvir* Ravidasvir
IMPLEMENTATION PROJECTS * Fexinidazole for _T.b. gambiense_* NECT
* SSG&PM (East Africa) * New VL treatments (South Asia) * Benznidazole paediatric dosage forms * Super-booster therapy for children with HIV/TB * 2-in-1 LPV/r pellets and ABC/3TC or AZT/3TC* ASAQ
* ASMQ
__ OPEN INNOVATION
DND_i_ and partners are making data available to the scientific community. See open innovation initiatives ____ ACHIEVEMENTS
8 new treatments delivered, recommended, and implementedASAQ Malaria
ASMQ Malaria
NECT Sleeping Sickness SSG&PM Leishmaniasis New treatments SouthAsiaLeishmaniasis
Paediatric
benznidazoleChagas
Super-booster
therapy HIV/TBPaediatric HIV FexinidazoleSleepingSickness
YOUTUBE
DND_I_: 15 YEARS OF PUTTING PATIENTS BEFORE PROFITS More DND_i_ videos on YouTube __PUBLICATIONS
PUBLICATIONS
15 YEARS OF NEEDS-DRIVEN INNOVATION FOR ACCESS KEY LESSONS, CHALLENGES, AND OPPORTUNITIES FOR THE FUTUREDownload
See all publicationsABOUT DND_I_
Drugs for Neglected Diseases _initiative_ (DND_i_) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments forneglected patients.
LEARN MORE
* Vision & Mission
* Business Plan
* DND_i_‘s Model
* Diseases & Projects* Portfolio
* Treatments developed* Clinical Trials
* Annual Report
* Scientific Articles* Contact Us
WORK WITH US
* Donate
* Partnership
* Requests for Proposals* Jobs
DND_I_ WORLDWIDE
* DND_i_ regional offices * DND_i_ Japan のサイトへはこちらから. __ * DND_i_ Latin America website __ * DND_i_ North America website __CONNECT
* __ Facebook
* __ Twitter
* __ Instagram
* __ LinkedIn
* __ YouTube
* __ RSS
* __ Events
NEWSLETTER
Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy . You can unsubscribe any time.I WANT TO RECEIVE
* E-news
* Media Releases and Statements* PRIVACY POLICY
* TERMS OF USE
* ACCEPTABLE USE POLICY* COOKIE POLICY
* _Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 SwitzerlandLicense_
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy .Close
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0